title: Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
abstract: OBJECTIVE
  Therapy with suramin sodium has been associated with photophobia, iritis, optic atrophy, and vortex keratopathy. We studied the ocular findings in patients who underwent treatment with suramin sodium for metastatic cancer of the prostate.
  
  
  METHODS
  In a prospective study, 114 patients who underwent treatment with suramin sodium for cancer of the prostate had an ophthalmologic examination with two weeks of onset of treatment and two weeks after termination of therapy. Additional examinations were performed on patients who developed ocular symptoms during suramin sodium therapy.
  
  
  RESULTS
  Nineteen (16.6%) of 114 patients developed ocular symptoms and signs while taking suramin sodium. Thirteen of these patients developed bilateral corneal epithelial whorllike deposits. In ten patients, the corneal deposits were associated with foreign body sensation and lacrimation. Symptoms in all of these patients resolved with topical lubricants. Three patients developed asymptomatic corneal deposits. Seven patients had blurred vision and were found to have a mean hyperopic shift in refractive error of 1.13 +/- 0.45 diopters (range, 0.75 to 2.00 diopters) that persisted throughout their treatment course. None of these patients had a decrease in best-corrected visual acuity.
  
  
  CONCLUSIONS
  In this study, ocular symptoms and signs associated with suramin sodium were common but were not considered a dose-limiting toxicity. Hyperopic shift in refractive error is a previously unreported ocular finding in association with suramin sodium therapy.
authors.affiliation: Department of Ophthalmology, University of Maryland Hospital, Baltimore, 21201, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Hemady
authors.forename: V J
authors.initials: VJ
authors.lastname: Sinibaldi
authors.forename: M A
authors.initials: MA
authors.lastname: Eisenberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003316:Corneal Diseases / Q000139:chemically induced / Q000175:diagnosis; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012030:Refractive Errors / Q000139:chemically induced / Q000175:diagnosis; D013498:Suramin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced / Q000175:diagnosis
chemical_list: D000970:Antineoplastic Agents; D013498:Suramin